Tag: biotechnology
-
Synthetic Bio Platform Finds Potential Superbug Antibiotic
Researchers at University of California in San Diego created a process for cloning synthetic gene clusters from marine bacteria that generate molecules with therapeutic potential, and produced an antibiotic candidate to treat previously drug-resistant infections. The team led by UC-San Diego oceanography and pharmacy professor Bradley Moore, published its findings yesterday online in the journal…
-
Cancer Organizations, Biotech Partner on Drug Discovery
Institute of Cancer Research and Cancer Research Technology in London, and the drug discovery company Nuevolution A/S in Copenhagen, are collaborating on identifying leads for new cancer treatments that act on a promising biological pathway. The agreement includes the option to co-develop therapies from candidates identified in the project, but financial aspects of the deal…
-
European Venture Licenses Biotech Drought-Resistant Traits
Genective, a joint venture between German and French seed companies to develop new corn varieties, is licensing engineered gene science from the biotechnology company Arcadia Biosciences Inc. in Davis, California. Arcadia Biosciences will receive initial, milestone, and sales royalty payments under the agreement, but the dollar amount of the deal was not disclosed. Arcadia Biosciences…
-
Biotech, National Lab Partner on Gas-to-Liquid Conversion
Calysta Energy, a biotechnology company in Menlo Park, California and Lawrence Livermore National Laboratory in Livermore, California are developing a biological process for converting methane to liquid fuel. Financial aspects of the agreement were not disclosed. Livermore National Lab is a facility of the U.S. Department of Energy. The project aims to devise a technique…
-
Regeneron, Geisinger Health to Partner on Genetic Sequencing
Regeneron Pharmaceuticals Inc. in Tarrytown, New York and Geisinger Health System, a health care provider in Pennsylvania, are studying genetic causes of disease among the 2.6 million residents in areas served by Geisinger’s facilities. Financial terms of the five-year agreement were not disclosed. Under the deal, Geisinger will collect blood specimens from 100,000 Geisinger patients…
-
Clinical Trial to Test Safety of MRSA Drug Candidate
Enanta Pharmaceuticals, a biotechnology company in Watertown, Massachusetts, is starting an early-stage clinical trial of an antibiotic to treat methicillin-resistant Staphylococcus aureus or MRSA infections. The drug, code-named EDP-788, is being developed under a contract with National Institute of Allergy and Infectious Diseases, part of National Institutes of Health. MRSA is a bacteria resistant to many…
-
DNA Diagnostics Company to Crowdfund Malaria Testing Device
QuantuMDx, a biotechnology company in Newcastle, U.K. says it will start a crowdfunding campaign next month to finance development and field trials of a handheld device to test for malaria. The device is an application of its Q-POC point-of-care diagnostics system, which will be the subject of an Indiegogo campaign beginning 12 February. The company,…
-
MedImmune, Biotech to Partner on Cancer Immunotherapies
MedImmune in Gaithersburg, Maryland, the biologics division of pharmaceutical company AstraZeneca, and Immunocore Ltd. in Oxford, U.K. will develop cancer treatments that harness the body’s immune system, based on Immunocore’s technology. The deal will pay Immunocore, for each therapy program licensed by MedImmune, $20 million initially and another $300 million in milestone payments, as well…
-
Stem Cell Therapy Aids Patient with ALS, Myasthenia Gravis
BrainStorm Cell Therapeutics Inc., in New York and Israel, reports a patient with the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and myasthenia gravis responded with improved motor and cognitive functions after stem cell treatments developed by the company. Researchers from Israeli medical centers and research institutes, and the Mayo Clinic in the U.S. report the…
-
Clinical, Drug Discovery Biotech Companies Announce Merger
Senesco Technologies, a clinical stage biotechnology company in Bridgewater, New Jersey says it has a non-binding merger agreement with Fabrus Inc. in La Jolla, California, a drug-discovery biotechnology firm. Financial details of the merger were not disclosed, although the companies plan to reveal the terms when they finalize the agreement in early 2014. Senesco develops…